Fate of 'BioShield' Bill for Anti-Terror Drugs Unclear

Congress this week is expected to take up a $6 billion bill for developing tests, treatments and vaccines against bioterrorism. Known as Project BioShield, the plan aims to create research incentives for the private sector. But many drug and biotech firms say without protections from potential lawsuits, the bill won't do much to stimulate drug development. Hear NPR's Julie Rovner.

Copyright © 2004 NPR. For personal, noncommercial use only. See Terms of Use. For other uses, prior permission required.

Copyright © 2004 NPR. All rights reserved. No quotes from the materials contained herein may be used in any media without attribution to NPR. This transcript is provided for personal, noncommercial use only, pursuant to our Terms of Use. Any other use requires NPR's prior permission. Visit our permissions page for further information.

NPR transcripts are created on a rush deadline by a contractor for NPR, and accuracy and availability may vary. This text may not be in its final form and may be updated or revised in the future. Please be aware that the authoritative record of NPR's programming is the audio.

Comments

 

Please keep your community civil. All comments must follow the NPR.org Community rules and terms of use, and will be moderated prior to posting. NPR reserves the right to use the comments we receive, in whole or in part, and to use the commenter's name and location, in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.